Semax 10mg + Selank 10mg

Semax 10mg + Selank 10mg Blend is Signal Labs' dual neuropeptide research preparation containing Semax (10mg) and Selank (10mg) co-lyophilised in a single vial. Both components are independently HPLC-verified to greater than or equal to 98% purity before combination. This blend targets researchers studying multiple neurochemical systems simultaneously — Semax contributing ACTH(4-10)-derived BDNF/monoaminergic biology and Selank contributing tuftsin-derived GABAergic/opioidergic biology — in a single reconstitution.

Semax (Met-Glu-His-Phe-Pro-Gly-Pro, MW approximately 887 g/mol) is an analogue of ACTH(4-10) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. Its published research profile centres on BDNF expression changes in hippocampal and cortical cell models, dopaminergic system modulation in striatal preparations, serotonergic pathway interactions, and neuroprotective effects in hypoxia and ischaemia research models. BDNF/TrkB signalling through PI3K/Akt and MAPK/ERK underlies Semax's connections to synaptic plasticity, LTP, and neurogenesis biology.

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro, MW approximately 863 g/mol) is a tuftsin-derived heptapeptide with published research in GABAergic signalling modulation (GABA-A receptor interactions), enkephalin degradation inhibition (prolonging endogenous opioid peptide activity by inhibiting neprilysin and aminopeptidase M), BDNF expression changes, and immunomodulatory effects in lymphocyte models. Both compounds are registered pharmaceuticals in Russia with published clinical safety data.

The mechanistic complementarity of the Semax + Selank combination provides multi-system neurochemical coverage: Semax targets monoaminergic (dopamine, serotonin) and neurotrophin (BDNF/TrkB) pathways; Selank targets GABAergic and opioidergic (enkephalin system) pathways. These systems interact extensively in hippocampal and cortical circuits involved in cognitive function, stress resilience, and mood regulation, but are mechanistically distinct enough that the combination provides complementary rather than redundant coverage.

Both compounds share the Pro-Gly-Pro C-terminal stability extension — a deliberate design feature of both Russian peptide research programmes that provides carboxypeptidase resistance and may contribute independent bioactivity through Pro-Gly-Pro's leukocyte chemotactic properties.

For mechanistic dissection using the blend: run four parallel treatment groups — vehicle (0.1% DMSO), Semax alone (10mg individual product), Selank alone (10mg individual product), and Semax+Selank blend. At matched molar concentrations (approximately 565nM each component at 0.5mg/mL reconstitution of each individual 10mg vial). For BDNF research (Semax-driven): measure BDNF mRNA (qRT-PCR, exon IV promoter transcript) and BDNF protein (ELISA) in hippocampal cell models at 24 hours. For GABAergic research (Selank-driven): measure GABA-A receptor-mediated chloride flux (MQAE chloride indicator dye) in hippocampal neurons. Additive effects in the blend (sum equals the combination) confirm independent non-interacting mechanisms; synergistic effects (combination greater than sum) suggest pathway crosstalk. Total vial: 20mg (10mg + 10mg). Reconstitute in bacteriostatic water. Store lyophilised at -20°C. For laboratory and analytical research purposes only.